Can drug repurposing strategies be the solution to the COVID-19 crisis?
Carolina L. Bellera, Manuel A. Llanos, Melisa E. Gantner, Santiago Rodrı́guez, Luciana Gavernet, Marcelo A. Comini, Alan Talevi
Abstract
: Most of the current clinical trials on potential COVID-19 treatments are, in fact, drug repurposing examples. In October 2020, the FDA approved a repurposed antiviral, remdesivir, as the first treatment for COVID-19. Considering the high expectations invested in approaching therapeutic solutions, the scientific community must be careful not to raise unrealistic expectations. Today more than ever, the conclusions drawn in scientific reports have to be fully supported by the level of evidence, avoiding any sort of unfounded speculation.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)RepurposingDrug repositioning2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicDrugBusinessMedicinePharmacologyVirologyBiologyDiseaseInfectious disease (medical specialty)PathologyEcologyOutbreakCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19